Disclosed positions

Estimated from their latest filings — positions may have changed since

$6.59M

combined est. value

Stock	Shares	Price	Value	Weight	As of
TVTXTravere Therapeutics, Inc.	112,770	$58.47	$6.59M	100%	2026-06-22

TVTX

Travere Therapeutics, Inc.

$6.59M

112,770 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 7

Stock	Transaction	Date	~6mo later
TVTXTravere Therapeutics, Inc.	Gift — · 468 sh	2026-06-22	—
TVTXTravere Therapeutics, Inc.	Sell $7.6K · 232 sh	2026-02-04	—
TVTXTravere Therapeutics, Inc.	Sell $49.7K · 1,547 sh	2026-02-04	—
TVTXTravere Therapeutics, Inc.	Sell $223.4K · 6,956 sh	2026-02-03	—
TVTXTravere Therapeutics, Inc.	Grant — · 28,130 sh	2026-01-31	—
TVTXTravere Therapeutics, Inc.	Sell $16.8K · 445 sh	2026-01-06	—
TVTXTravere Therapeutics, Inc.	Sell $81.6K · 2,031 sh	2026-01-05	—
TVTXTravere Therapeutics, Inc.	Sell $630.0K · 15,000 sh	2025-12-24	—
TVTXTravere Therapeutics, Inc.	Exercise $133.9K · 15,000 sh	2025-12-24	—
TVTXTravere Therapeutics, Inc.	Sell $11.9K · 815 sh	2025-07-01	—

TVTXGift

2026-06-22 · Travere Therapeutics, Inc.

468

—

TVTXSell

2026-02-04 · Travere Therapeutics, Inc.

$7.6K

—

TVTXSell

2026-02-04 · Travere Therapeutics, Inc.

$49.7K

—

TVTXSell

2026-02-03 · Travere Therapeutics, Inc.

$223.4K

—

TVTXGrant

2026-01-31 · Travere Therapeutics, Inc.

28,130

—

TVTXSell

2026-01-06 · Travere Therapeutics, Inc.

$16.8K

—

TVTXSell

2026-01-05 · Travere Therapeutics, Inc.

$81.6K

—

TVTXSell

2025-12-24 · Travere Therapeutics, Inc.

$630.0K

—

TVTXExercise

2025-12-24 · Travere Therapeutics, Inc.

$133.9K

—

TVTXSell

2025-07-01 · Travere Therapeutics, Inc.

$11.9K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.